Back to results
US 2016/0355814 A1Published application
Mir-155 inhibitors for treating cutaneous t cell lymphoma (ctcl)
AssigneeMiragen Therapeutics, Inc.
InventorsDavid RODMAN, Anita SETO, Christina DALBY, Aimee JACKSON, Xuan BEATTY
Life of this patent
Estimating the term…
Abstract
The present invention provides oligonucleotide inhibitors of miR-155 and compositions thereof. The invention further provides methods for treating cancer such as a T cell lymphoma in a subject by administering to the subject an oligonucleotide inhibitor of miR-155. The invention also provides methods for reducing or inhibiting the proliferation of malignant T cells by administering an oligonucleotide inhibitor of miR-155.
Claims30
An oligonucleotide inhibitor of miR-155 comprising a sequence of 11 to 16 nucleotides, wherein
- said oligonucleotide inhibitor is fully complementary to a mature sequence of miR-155 and has a full phosphorothioate backbone;
- and
- wherein at least the first three nucleotides from the 3′ end of said oligonucleotide inhibitor are locked nucleotides and at least the second nucleotide from the 5′ end of the oligonucleotide inhibitor is a deoxyribonucleic acid (DNA) nucleotide.
Dependencies are inferred from the claim text.